Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2023 07:32 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
September 29, 2023 07:30 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
August 10, 2023 16:05 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
August 03, 2023 17:32 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
July 03, 2023 06:01 ET | Source: Zealand Pharma

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396

Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
June 24, 2023 11:35 ET | Source: Zealand Pharma

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
June 07, 2023 08:30 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
May 31, 2023 16:30 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics to Present at Jefferies Healthcare Conference

SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
May 25, 2023 16:30 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
May 18, 2023 16:30 ET | Source: Structure Therapeutics Inc.

Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...